feedback

Chair

David T. Rubin, MD
Professor of Medicine
Chief, Section of Gastroenterology,
Hepatology, and Nutrition
University of Chicago Medicine
Chicago, IL


Faculty

Uma Mahadevan, MD
Professor of Medicine, UCSF Medical Center
Co-Medical Director, UCSF Center for Colitis
and Crohn’s Disease
San Francisco, CA


Activity Details

Credit Type: AMA PRA Category 1 Credit
Credit Amount: 0.5
Release Date: October 7, 2016
Expiration Date: October 7, 2017
Estimated Time to Complete Activity: 30 minutes
Registration Required: No
Fee for Activity: There is no fee for participating in this activity.

Provider

This activity is provided by Imedex®, LLC.

Overview

As clinical paradigms for UC continue to change, there is also an emergence of novel therapeutic agents currently in development that target a multiplicity of inflammatory pathways. Moreover, serologic, genetic, and inflammatory markers have been shown to be predictive of disease activity in patients with UC and have the potential of optimizing therapeutic response, leading to a more personalized approach to therapy—so called ‘precision medicine’. This activity features expert faculty discussing the mechanism of action of current and novel agents designed to treat UC, evaluate clinical trials data and assess potential clinical applications.

Learning Objectives

After completing this educational activity, participants should be better able to:

  • Relate the pathophysiologic mechanisms of UC with therapeutic targets of intervention, with particular focus on biologics and immunomodulatory agents
  • Summarize novel and emerging therapeutic regimens, including single-agent- and combination regimens, based on recently published data and findings from ongoing clinical trials for the treatment of patients with UC

Target Audience

This educational activity is designed for gastroenterologists, IBD specialists, gastroenterology nurses, gastroenterology mid-level providers and gastrointestinal surgeons, and other health care professionals (physicians-in-training, nurses, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with UC.

Continuing Education



Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex, LLC designates this enduring educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 0.5 hour of Category 1 credit for completing this program.

In order to receive credit, participants must successfully complete the post-test and complete the online evaluation form. You will receive an online CME statement of credit to print for your records.

Support

The following companies have provided unrestricted educational grants in support of this activity: Pfizer.

Disclosure of Financial Relationships

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are instructed to provide a balanced view of therapeutic options, clinically relevant and evidence-based recommendations, and avoid bias towards any specific commercial product and/or service.

Faculty Disclosures

All faculty participating in an Imedex activity are required to disclose relevant financial relationships that may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.

1=grant/research support 2=consultant 3=speaker’s bureau 4=stock shareholder 5=other support

Uma Mahadevan, MD: Abbvie(2), BMS(2), Celgene(2), Janssen(2), Millennium(1), Pfizer(2), Prometheus(1), Takeda(2), UCB(1,2).

David T. Rubin, MD: AbbVie(1,2), American College of Gastroenterology(5), Amgen(2), Cornerstones Health, Inc.(5), Emmi(2), Genentech(1,2), Janssen(1,2), Pfizer(2), Prometheus Laboratories(1,2), Shire(1,2), Takeda(1,2), UCB(1,2).

All materials are included with the permission of the authors.

Imedex Staff Disclosures

All Imedex staff members who are in a position to control content of this activity have no financial relationships with any commercial interests, except for the following:

Chris Bolwell owns shares of stock of GlaxoSmithKline.

Unapproved Uses

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.

The opinions expressed in this webcast are the opinions of the presenters and do not necessarily reflect the opinions of Imedex.

Disclaimer

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

About Imedex

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED. 

© 2016 Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.

For comments or inquiries, please contact:
Imedex, LLC
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Fax: +1(770) 751-7334
Email: elearning@imedex.com

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.